Literature DB >> 21755809

Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America.

George R Bailie1, Walter H Hörl, Jan-Jaap Verhoef.   

Abstract

Spontaneously-reported rates of adverse events (AEs) of intravenous (i.v.) iron products have not been compared since 2007. AEs in Europe (Eur) and North America (NA) have never been compared. New products have been marketed and many changes in prescribing habits have occurred since then, and the effect on AEs reporting is unclear. It was hypothesized that changing practices for i.v. iron products has caused changes in the rates of serious AEs and large differences exist between Eur and NA. Rates of AEs for three i.v. iron preparations (iron sucrose [IS], ferric gluconate [FG] and high and low MW iron dextran [HMWID, LMWID]) were compared by product and continent from January 1, 2003 to June 30, 2009 for selected countries in Eur and NA, using the Uppsala Monitoring Center's database. Rates of total, anaphylaxis and other serious allergic AEs were calculated as number of AEs divided by i.v. iron sales standardized to 100 mg dose equivalents (DEq) of iron. Quarterly sales (millions of 100 mg DEq of iron) increased from the first quarter 2003 to the end of the second quarter of 2009 by 1% for FG, 16% for IS and 2% for ID. Total AEs for NA plus Eur were similar for FG and IS, but total AEs were 6- to 7-fold higher for ID. Rates of anaphylaxis were 6- to 11-fold higher in Eur plus NA combined for ID than for IS or FG. In NA, there were substantially higher reports for total, anaphylaxis and other serious allergic AEs with FG compared to IS, whereas the reverse was the case in Eur. Odds ratios (OR) showed higher risks of anaphylaxis with FG in NA vs. Eur (OR = 4.40, P < 0.0001) and lower risks with IS (OR = 0.24, P < 0.0001). Odds of anaphylaxis with LMWID in Eur vs. FG and IS were 42.08 and 16.92 (both P < 0.0001), respectively. In NA, odds of anaphylaxis with ID vs. FG and IS were 2.36 and 17.73 (both P < 0.0001), respectively. Differences between NA and Eur may be related to varied treatment practices. ID had the highest rates of all types of AEs, and IS and FG had a continued trend for lowest rates of AEs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21755809     DOI: 10.1055/s-0031-1296198

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

1.  Double bull's eye for post-operative intravenous iron in patient blood management: better outcome and cost-effective.

Authors:  Giancarlo M Liumbruno; Gioia Grazzini
Journal:  Blood Transfus       Date:  2013-12-04       Impact factor: 3.443

2.  Outcomes Associated with Conventional Accelerated Versus Once-Weekly IV Iron Therapy in Outpatients Undergoing Hemodialysis.

Authors:  Marta Malkinska; Wasim S El Nekidy; Maher M El-Masri; Albert Kadri; Christine Donaldson; Derrick Soong
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

Review 3.  Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.

Authors:  J Szebeni; S Fishbane; M Hedenus; S Howaldt; F Locatelli; S Patni; D Rampton; G Weiss; J Folkersen
Journal:  Br J Pharmacol       Date:  2015-10-25       Impact factor: 8.739

4.  Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.

Authors:  Jorge Eduardo Toblli; Gabriel Cao; Leda Oliveri; Margarita Angerosa
Journal:  Inflamm Allergy Drug Targets       Date:  2012-02

5.  Authors' reply to Schaffalitzky de Muckadell and colleague's Comment on "Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017".

Authors:  Birgit Ehlken; Lennart Nathell; Annegret Gohlke; Derya Bocuk; Massoud Toussi; Stefan Wohlfeil
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

6.  Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017.

Authors:  Birgit Ehlken; Lennart Nathell; Annegret Gohlke; Derya Bocuk; Massoud Toussi; Stefan Wohlfeil
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

7.  A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia.

Authors:  Heinz Ludwig; M Aapro; C Bokemeyer; J Glaspy; M Hedenus; T J Littlewood; A Österborg; B Rzychon; D Mitchell; Y Beguin
Journal:  Support Care Cancer       Date:  2014-08       Impact factor: 3.603

8.  Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake.

Authors:  Min Wu; Dajun Sun; Katherine Tyner; Wenlei Jiang; Rodney Rouse
Journal:  Nanomaterials (Basel)       Date:  2017-12-15       Impact factor: 5.076

9.  Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures.

Authors:  Lennart Nathell; Annegret Gohlke; Stefan Wohlfeil
Journal:  Drug Saf       Date:  2020-01       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.